Impact of Blood‐Based Biomarkers on Access to Alzheimer's Disease Treatments: A Simulation Study in Japan

Abstract

Background: New disease‐modifying therapies (DMTs) targeting amyloid‐beta (Aβ) for mild cognitive impairment and mild dementia due to Alzheimer's disease (AD) currently require brain Aβ confirmation using amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) biomarkers.

The paper